ASR Vermogensbeheer N.V. Acquires 163 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

ASR Vermogensbeheer N.V. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,926 shares of the biopharmaceutical company’s stock after purchasing an additional 163 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Alnylam Pharmaceuticals were worth $2,910,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Bayforest Capital Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 39 shares during the last quarter. Fulton Bank N.A. grew its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 46 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 49 shares during the last quarter. Edmond DE Rothschild Holding S.A. grew its holdings in Alnylam Pharmaceuticals by 18.2% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 49 shares during the last quarter. Finally, Lindbrook Capital LLC grew its holdings in Alnylam Pharmaceuticals by 9.2% in the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 50 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ ALNY opened at $456.35 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The stock has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The firm has a 50-day moving average of $441.57 and a 200 day moving average of $338.75. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same period last year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals’s revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Evercore ISI raised their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Truist Financial assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a “buy” rating and a $385.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Saturday, September 27th. Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Finally, Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $439.58.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director directly owned 16,804 shares of the company’s stock, valued at $7,561,800. This trade represents a 40.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director directly owned 911 shares of the company’s stock, valued at approximately $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.